This company develops tissue-engineered implants derived from human cells that can grow and regenerate with the patient's own tissue after implantation. These off-the-shelf implants aim to improve outcomes for cardiovascular disease patients by overcoming limitations of existing synthetic implants.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular implants made from synthetic or animal-derived materials lack the fundamental properties of living tissue, failing to grow or regenerate and often leading to complications like infection, thrombosis, and the need for replacement surgeries. This is particularly problematic for pediatric patients who require multiple high-risk surgeries as they outgrow their implants.
Solution
LifeMatrix Technologies AG develops biomimetic cardiovascular implants derived from human cells that can grow and regenerate with the patient's own tissue. Their tissue-engineered implants, including heart valves and vascular grafts, are designed to transform into living tissue after implantation, overcoming the limitations of existing synthetic and animal-derived materials. The implants are created using a patented bio-engineering platform that utilizes biodegradable polymer scaffolds seeded with human donor cells to form a cell-free human matrix. This matrix is non-immunogenic, scalable, and can be stored for off-the-shelf availability, allowing the patient's own cells to infiltrate and remodel the implant into functional tissue.
Target Audience
The primary target audience includes cardiovascular surgeons, interventional cardiologists, and pediatric cardiac specialists seeking advanced implant solutions for patients with cardiovascular disease, especially those requiring long-lasting, regenerative implants.
Features
- Biomimetic implants engineered from human donor cells and biodegradable polymer scaffolds
- Cell-free human extracellular matrix that promotes tissue remodeling and integration
- Scalable manufacturing process using master cell banks for cost-effective production
- Capacity for self-renewal, remodeling, and growth after implantation
- Potential to eliminate the need for repeat interventions and improve long-term outcomes
- Customizable shapes and sizes for various cardiovascular applications, including heart valves, vascular grafts, and pediatric shunts
- Compatibility with surgical and minimally invasive transcatheter procedures